Clin Trans Gastroenterology:预防性抗结核治疗与接受抗TNF治疗的克罗恩病患者疾病进展加速有关

2022-07-06 xuyihan MedSci原创

克罗恩病(crohn disease,CD),又称局限性回肠炎、局限性肠炎、节段性肠炎和肉芽肿性肠炎、也译为克隆氏病,是一种原因不明的肠道炎症性疾病。

克罗恩病 (CD) 是一种复杂且易复发的胃肠道疾病,能逐渐发展为狭窄或穿透性病变。抗肿瘤坏死因子-α(抗-TNFα)药物等生物制剂彻底改变了CD的治疗方法,并在实现临床缓解和黏膜愈合方面具有公认的功效。然而,机会性感染的风险,例如激活潜伏性结核感染 (LTBI),仍然是一个棘手的问题。为防止LTBI激活,指南建议在开始抗TNF治疗之前进行结核病暴露史、干扰素-γ释放试验、结核菌素皮肤试验和胸部影像学检查。另外指南建议对患有LTBI的CD患者进行预防性抗结核治疗 (ATT),例如异烟肼 (INH) 和利福平 (RFP) 单药治疗或联合治疗,这已被证明是降低接受抗结核药物治疗的CD患者TB活化的有效策略。

然而,预防性 ATT 可能会导致潜在的副作用。最近的一项研究引起了对在CD诊断前有经验性ATT治疗的 CD 患者的担忧,因为他们更容易出现肠道狭窄。因此,本项研究的目的是比较 ATT 使用者和非 ATT 使用者在接受抗 TNF 治疗的 CD 患者中疾病进展的差异。

为此,研究人员在出现炎症行为 (B1) 并接受抗 TNF 药物治疗的 CD 患者中进行了一项回顾性、多中心研究。疾病进展被定义为出现狭窄(B2)或穿透(B3)的表型。ATT使用者与非 ATT使用者进行了的倾向得分相匹配。生存和多变量 Cox 分析用于确定与疾病进展相关的因素。

 

 

本项研究共招募了441名患者,包括295名ATT用户和146名非ATT用户,中位随访时间为3.15年。在1年、3年、5年和10年的随访后,ATT组的累积疾病进展率持续高于非 ATT组(P=0.031)。多变量Cox分析使用整体(风险比=2.22;95%置信区间:1.11-4.48; P=0.025)和倾向得分匹配队列(风险比=2.35;95%)将ATT确定为疾病进展的独立危险因素(置信区间:1.07–5.14;P= 0.033)。在亚组分析中,与接受ATT<4.5个月(P=0.005)和非ATT治疗(P=0.036)的患者相比,接受 ATT≥4.5个月的患者疾病进展率显着更高。

 

本项研究结果证实持续时间超过4.5个月的预防性ATT治疗与接受抗TNF治疗的CD患者的疾病进展相关。

原始出处:

Liu, Fen. Et al. Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study. Clinical and Translational Gastroenterology.2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2023-06-02 mfx808
  6. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2023-03-21 许安
  7. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-08-15 柳叶一刀
  9. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-07-06 ms4000001080920254

    学习了!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2070158, encodeId=4b3d20e0158ff, content=<a href='/topic/show?id=49d25514317' target=_blank style='color:#2F92EE;'>#抗TNF治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55143, encryptionId=49d25514317, topicName=抗TNF治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Sep 03 05:34:54 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065547, encodeId=5465206554e35, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 11 09:34:54 CST 2023, time=2023-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713085, encodeId=1df61e13085d5, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Feb 21 05:34:54 CST 2023, time=2023-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034876, encodeId=df0220348e61b, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Dec 27 14:34:54 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670814, encodeId=4e4f16e08148c, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Jun 02 16:34:54 CST 2023, time=2023-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2073570, encodeId=99f820e3570a3, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Mar 21 23:34:54 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907789, encodeId=a7c5190e78909, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Thu Sep 08 20:34:54 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657656, encodeId=5dec165e656b0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Aug 15 12:34:54 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230907, encodeId=e469123090e80, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72c5725505, createdName=ms4000001080920254, createdTime=Wed Jul 06 13:50:17 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230902, encodeId=7af71230902a5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 06 13:01:15 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-07-06 yangchou

    好文章,谢谢分享。

    0

相关资讯

Lancet:乌司奴单抗 vs 阿达木单抗治疗克罗恩病头对头研究结果出炉

头对头SEAVUE试验的结果显示,对于患有中重度克罗恩病的生物制剂初治成人患者,使用

慢性炎症性皮肤病患者会影响炎症性肠病的发生率吗?

最近一些研究将各种慢性炎症性皮肤病(CISD)与炎症性肠病(IBD)联系起来,但结论不一。我们比较了溃疡性结肠炎(UC)和克罗恩病(CD)在患有CISD的患者与没有CISD的类似人员中的发病率。

综述:2022年欧洲克罗恩和结肠炎组织(ECCO)会议进展

中华炎性肠病杂志,2022年第6卷第2期

Gastroenterology:接受腹部手术的炎症性肠病患者术前肿瘤坏死因子抑制剂的治疗的安全性分析

克罗恩病在疾病早期对患者的影响并不大,但如果不及时进行治疗,发展到后期则会对患者造成巨大的伤害。一旦发现有相关症状,建议患者尽早到医院进行治疗。

IBD: 乌司奴单抗在伴有和不伴有自身免疫性皮肤病的克罗恩病中的疗效差异

克罗恩病是一种原因不明的肠道炎症性疾病,在胃肠道的任何部位均可发生,但多发于末端回肠和右半结肠。

AP&T: 超声愈合与克罗恩病患者的长期预后改善有关

克罗恩病是一种无法治愈的终生性疾病,在人体受到环境和遗传易感因素的作用下,影响到肠黏膜免疫,造成非特异性的炎症性疾病。